全文获取类型
收费全文 | 351篇 |
免费 | 13篇 |
专业分类
儿科学 | 27篇 |
基础医学 | 36篇 |
口腔科学 | 1篇 |
临床医学 | 18篇 |
内科学 | 78篇 |
皮肤病学 | 17篇 |
神经病学 | 10篇 |
特种医学 | 6篇 |
外科学 | 67篇 |
综合类 | 3篇 |
预防医学 | 11篇 |
眼科学 | 2篇 |
药学 | 17篇 |
肿瘤学 | 71篇 |
出版年
2024年 | 1篇 |
2023年 | 3篇 |
2022年 | 4篇 |
2021年 | 16篇 |
2020年 | 3篇 |
2019年 | 12篇 |
2018年 | 12篇 |
2017年 | 9篇 |
2016年 | 7篇 |
2015年 | 7篇 |
2014年 | 7篇 |
2013年 | 18篇 |
2012年 | 37篇 |
2011年 | 16篇 |
2010年 | 8篇 |
2009年 | 13篇 |
2008年 | 12篇 |
2007年 | 9篇 |
2006年 | 19篇 |
2005年 | 16篇 |
2004年 | 8篇 |
2003年 | 12篇 |
2002年 | 8篇 |
2001年 | 8篇 |
2000年 | 6篇 |
1999年 | 16篇 |
1998年 | 9篇 |
1997年 | 2篇 |
1995年 | 3篇 |
1994年 | 3篇 |
1992年 | 8篇 |
1991年 | 3篇 |
1990年 | 6篇 |
1989年 | 10篇 |
1988年 | 4篇 |
1987年 | 3篇 |
1986年 | 7篇 |
1985年 | 3篇 |
1984年 | 3篇 |
1983年 | 1篇 |
1982年 | 1篇 |
1979年 | 4篇 |
1976年 | 1篇 |
1975年 | 1篇 |
1973年 | 1篇 |
1972年 | 2篇 |
1971年 | 2篇 |
排序方式: 共有364条查询结果,搜索用时 15 毫秒
61.
Localized vaginal/uterine rhabdomyosarcoma—results of a pooled analysis from four international cooperative groups 下载免费PDF全文
Veronique Minard‐Colin David Walterhouse Gianni Bisogno Helene Martelli James Anderson David A. Rodeberg Andrea Ferrari Meriel Jenney Suzanne Wolden Gianluca De Salvo Carola Arndt Johannes H. M. Merks Soledad Gallego Dominique Schwob Christine Haie‐Meder Christophe Bergeron Michael C. G. Stevens Odile Oberlin Douglas Hawkins 《Pediatric blood & cancer》2018,65(9)
1 Background
Vaginal/uterine rhabdomyosarcoma (VU RMS) is one of the most favorable RMS sites. To determine the optimal therapy, the experience of four cooperative groups (Children's Oncology Group [COG], International Society of Pediatric Oncology (SIOP) Malignant Mesenchymal Tumor Group [MMT], Italian Cooperative Soft Tissue Sarcoma Group [ICG], and European pediatric Soft tissue sarcoma Study Group [EpSSG]) was analyzed.2 Procedure
From 1981 to 2009, 237 patients were identified. Median age (years) at diagnosis differed by tumor location; it was 1.9 for vagina (n = 160), 2.7 for uterus corpus (n = 26), and 13.5 for uterus cervix (n = 51). Twenty‐eight percent of patients received radiation therapy (RT) as part of primary therapy (23% COG, 27% MMT, 46% ICG, and 42% EpSSG), with significant differences in the use of brachytherapy between the cooperative groups (23% COG, 76% MMT, 64% ICG, and 88% EpSSG).3 Results
Ten‐year event‐free (EFS) and overall survival (OS) were 74% (95% CI, 67–79%) and 92% (95% CI, 88–96%), respectively. In univariate analysis, OS was inferior for patients with uterine RMS and for those with regional lymph node involvement. Although EFS was slightly lower in patients without initial RT (71% without RT vs. 81% with RT; P = 0.08), there was no difference in OS (94% without RT vs. 89% with RT; P = 0.18). Local control using brachytherapy was excellent (93%). Fifty‐one (51.5%) of the 99 survivors with known primary therapy and treatment for relapse were cured with chemotherapy with or without conservative surgery.4 Conclusions
About half of all patients with VU RMS can be cured without systematic RT or radical surgery. When RT is indicated, modalities that limit sequelae should be considered, such as brachytherapy. 相似文献62.
Bergeron C Thiesse P Rey A Orbach D Boutard P Thomas C Schmitt C Scopinaro MJ Bernard F Stevens M Oberlin O 《European journal of cancer (Oxford, England : 1990)》2008,44(3):427-431
PurposeMany cooperative groups have reported on the chemo-sensitivity of rhabdomyosarcoma (RMS). Doxorubicin has been tested but remains a controversial treatment option. We report here the results of the up-front evaluation of the efficacy of doxorubicin in children and adolescents with high-risk metastatic RMS.Patients and methodsPatients younger than 18 years of age (>6 months) with newly diagnosed, histologically confirmed high-risk metastatic RMS were required to have measurable disease, to have undergone no prior chemotherapy or radiation therapy and to have normal liver, renal and cardiac function before treatment. Doxorubicin was administered intravenously over 48 h to a total dose of 60 mg/m2. Two courses were given separated by a 21 day interval. Response to therapy was assessed by diagnostic imaging after the second course. The study was designed as a two-stage procedure according to the multistep plan described by Fleming.ResultsTwenty patients were eligible for analysis. Median age at diagnosis was 9.8 years (range from 2 to 16). Thirteen of the 20 patients treated in the first step responded to treatment, corresponding to an overall response to doxorubicin of 65% [95% confidence interval (CI), 44–85%]. The rates of CR and PR were 5% [95% CI, 0–14%] and 60% [95% CI, 39–81%], respectively. Four (20%) patients had progressive disease, corresponding to a progression rate of 20% [95% CI, 2–38%].ConclusionThis window study provides the definitive demonstration of the efficacy of doxorubicin in untreated RMS. Given the inconclusive results obtained from previous studies using differing schedules chemotherapy incorporating doxorubicin, the next step should be a randomised study testing dose intensity in high-risk localised RMS. This issue is being addressed in a current European study (EpSSG RMS 2005). 相似文献
63.
Treatment of orbital rhabdomyosarcoma: survival and late effects of treatment--results of an international workshop. 总被引:1,自引:0,他引:1
O Oberlin A Rey J Anderson M Carli R B Raney J Treuner M C Stevens 《Journal of clinical oncology》2001,19(1):197-204
PURPOSE: Orbital rhabdomyosarcoma (RMS) historically has been associated with an excellent survival rate. The majority of patients are cured with the use of both chemotherapy and radiation therapy, but a significant number experience important late sequelae of treatment. In an attempt to determine optimal therapy in relation both to cure and to sequelae, the experience of the four international collaborative groups (Intergroup Rhabdomyosarcoma Study Group [IRSG], International Society of Paediatric Oncology [SIOP] Sarcoma Committee, German Collaborative Soft Tissue Sarcoma Group [CWS], and Italian Cooperative Soft Tissue Sarcoma Group [ICG] studies) was shared at an international workshop. PATIENTS AND METHODS: A total of 306 eligible patients were identified from group records (186 from IRS, 43 from SIOP MMT, 40 from CWS, and 37 from ICG). Median age was 6.8 years, and median follow-up was 6.5 years. Eighty percent of patients received radiation therapy (RT) as part of primary therapy, but there were significant differences in the use of RT between the individual groups (93% in IRSG, 76% in ICG, and 70% in CWS, but only 37% in the SIOP MMT group). RESULTS: At 10 years, event-free and overall survival for the whole cohort were 77% (range, 71% to 81%) and 87% (range, 82% to 92%), respectively. There was no difference in overall survival between the collaborative groups regardless of differences in the use of initial RT. In total, 34 (12%) of 273 survivors had not received RT, although this varied between the different groups (41% in the SIOP MMT group, 20% in CWS, 7% in ICG, and 6% in IRSG). There was no difference in overall survival for the whole cohort regardless of whether radiotherapy was used as part of initial therapy (86% at 10 years for both). CONCLUSION: These data suggest that a subset of patients with orbital RMS can be cured without systematic local therapy, although the total burden of treatment (primary therapy and treatment for relapse) must be taken into account when assessing the implications for late sequelae. 相似文献
64.
Brachytherapy in paediatric malignancies is rarely used, limited to expert institutions. The most frequent tumour sites treated with brachytherapy are gynaecological rhabdomyosarcomas, and prostate/bladder rhabdomyosarcomas. Ballistic advantages make brachytherapy technique the treatment of choice, with a high and selective protection of organs at risk. Techniques, brachytherapy modalities (low dose-rate, high dose-rate, pulsed dose-rate), doses and indications vary according to centres. Brachytherapy advantages are in relation with ballistic properties, allowing a very high dose to the target with normal tissue sparing. This review analyzes brachytherapy techniques, indications and results according to the two most frequent tumour sites: gynaecological and bladder/prostate tumours. This technique requires a muldisciplinary approach. 相似文献
65.
O. Oberlin D. Sarrazin J. Lemerle A. Boilletot G. Leverger G. Schaison 《Pediatric hematology and oncology》1985,2(1):65-70
Sixty children with Hodgkin's disease were clinically staged and treated by MOPP primary chemotherapy followed by 40 Gy nodal radiation limited to involved fields. Overall 5-year survival is 93% while relapse-free survival is 86%. Four patients relapsed. These results confirm that laparotomy no longer has a place in routine staging when chemotherapy is given to all patients and that radiotherapy of localized disease (IA and IIA) can be limited to involved fields. On the basis of these results and data of other published series, the French Society of Clinical Oncology and Hopital Saint Louis initiated a new joint national study to minimize the late effects of combined modality therapy without jeopardizing the good survival. Outlines and preliminary results of this study are presented. 相似文献
66.
A T Meadows E Baum F Fossati-Bellani D Green R D Jenkin B Marsden M Nesbit W Newton O Oberlin S G Sallan 《Journal of clinical oncology》1985,3(4):532-538
This paper presents an update from the Late Effects Study Group on 292 cases of second malignant neoplasms (SMN) occurring in individuals who were diagnosed with their first neoplasm in childhood. Data are presented regarding the types of first and second neoplasm, the therapy administered, and the predisposing factors. Of the 292 cases (308 SMN), the most common primary was retinoblastoma followed by Hodgkin's disease, soft-tissue sarcomas, and Wilms' tumor. This is not similar to the relative frequency of these cancers in children but rather reflects specific risk factors. Bone sarcomas were the most common SMN among the 208 SMN developing in previously irradiated sites while acute leukemia was the most common SMN unassociated with radiation. Known predisposing conditions to cancer were present in 73 cases; retinoblastoma was the most common of these, followed by neurofibromatosis. There were ten patients with three and three patients with four malignant neoplasms. In 14 patients, the cause of SMN was not suggested by known risk factors as these patients had negative family histories and received no radiation or chemotherapy. We note, therefore, that although most cases of SMN in survivors of childhood cancer can be attributed to radiation, genetic disease, chemotherapy, or combinations of these, unrecognized predisposition or chance may also play a role. 相似文献
67.
68.
69.
70.
Flavien Oberlin Sylvie Rozenberg Josette Guillemant Richard Dorent Geneviève Maistre Iradj Gandjbakhch Serge Guillemant Pierre Bourgeois 《Journal of bone and mineral metabolism》1994,12(Z1):S105-S109
Most studies find that precardiac transplantation patients are poorly mineralized; up to 35% of them suffer from vertebral
crush fracture after transplantation.
We studied 30 consecutives males cardiac transplant candidates. The mean age was 50.2±1.5 years (mean±SE). Creatinine clearance
(82.3±5.1 ml/mn), 25 OH vitamin D (8.9±0.7 ng/ml) and osteocalcin level (22.6±2.4 ng/ml) were in the normal ranges. Mean bone
mineral density was low either at lumbar spine (0.905±0.027 gr±cm2) or at femoral neck (0.829±0.021 gr/cm2) (Hologic QDR 1000). Mean Z scores were also low: −1.30±0.24 at lumbar spine, −1.61±0.19 at femoral neck. Parathormone (1-84)
level was elevated (53.1±6.8 ng/ml). Parathormone level was highly correlated with lumbar (r=0.512; p=0.004) or femoral (r=0.579;
p=0.001) bone mineral density as with lumbar (r=0.524; p=0.003) or femoral (r=0.606; p=0.0004) Z scores. 相似文献